Last reviewed · How we verify
Alemtuzumab infusion
Alemtuzumab is a monoclonal antibody that binds to CD52 on the surface of lymphocytes, leading to their destruction and depletion of T and B cells.
Alemtuzumab is a monoclonal antibody that binds to CD52 on the surface of lymphocytes, leading to their destruction and depletion of T and B cells. Used for Relapsing-remitting multiple sclerosis, Chronic lymphocytic leukemia (CLL), T-cell prolymphocytic leukemia.
At a glance
| Generic name | Alemtuzumab infusion |
|---|---|
| Sponsor | Johns Hopkins University |
| Drug class | monoclonal antibody (CD52-directed) |
| Target | CD52 |
| Modality | Small molecule |
| Therapeutic area | Immunology / Oncology |
| Phase | FDA-approved |
Mechanism of action
Alemtuzumab targets CD52, a glycoprotein expressed on B lymphocytes, T lymphocytes, and other immune cells. Upon binding, it triggers antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), resulting in rapid lymphocyte depletion. This immunosuppressive effect is used to treat autoimmune conditions and certain hematologic malignancies.
Approved indications
- Relapsing-remitting multiple sclerosis
- Chronic lymphocytic leukemia (CLL)
- T-cell prolymphocytic leukemia
Common side effects
- Infusion reactions (fever, chills, hypotension)
- Lymphopenia
- Infections (opportunistic and bacterial)
- Autoimmune complications (thyroiditis, ITP)
- Nausea and vomiting
- Headache
Key clinical trials
- Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study (PHASE1, PHASE2)
- Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists (PHASE1, PHASE2)
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases (PHASE1, PHASE2)
- Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide (EARLY_PHASE1)
- Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia (PHASE1, PHASE2)
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- HLA-Identical Sibling Renal Transplant Tolerance (NA)
- Immune Disorder HSCT Protocol (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alemtuzumab infusion CI brief — competitive landscape report
- Alemtuzumab infusion updates RSS · CI watch RSS
- Johns Hopkins University portfolio CI